Can an Acidic Beverage Reduce Interactions Between Proton Pump Inhibitors and Erlotinib?

  • David Planchard
  • Published 2016 in
    Journal of clinical oncology : official journal…


The past decade has been marked by the identification of multiple driver mutations that define new molecular subsets of non–small-cell lung cancer (NSCLC). This triggered the development of small-molecule tyrosine kinase inhibitors (TKIs), with a shift from intravenous to orally administered therapy, which is more flexible and convenient. Because TKIs are… (More)
DOI: 10.1200/JCO.2015.66.3344


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics